Evidence map›Paper›PMID 34088701›Full record

Trial reportDiabetes care2021

Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study.

Nina L Petrova, Nicholas K Donaldson, Maureen Bates, Wegin Tang, Timothy Jemmott, Victoria Morris, Tracy Dew, Lisa Meacock, David A Elias, Cajetan F Moniz and 1 more

Erratum issuedOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Burning Issues/Hot Topics: The Charcot Foot.Journal of clinical medicine · 2026
    Review
  6. Article
  7. Article
  8. [Progress in clinical diagnosis and treatment of diabetic Charcot neuroarthropathy of foot and ankle].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2023
    Article
  9. Controversies in the management of active Charcot neuroarthropathy.Therapeutic advances in endocrinology and metabolism · 2023
    Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Nina L PetrovaDiabetic Foot Clinic, King's College Hospital NHS Foundation Trust, London, U.K nina.petrova@nhs.net.ORCID 0000-0001-6937-6565
Nicholas K DonaldsonDiabetic Foot Clinic, King's College Hospital NHS Foundation Trust, London, U.K.
Maureen BatesDiabetic Foot Clinic, King's College Hospital NHS Foundation Trust, London, U.K.
Wegin TangDiabetic Foot Clinic, King's College Hospital NHS Foundation Trust, London, U.K.
Timothy JemmottDiabetic Foot Clinic, King's College Hospital NHS Foundation Trust, London, U.K.
Victoria MorrisDiabetic Foot Clinic, King's College Hospital NHS Foundation Trust, London, U.K.
Tracy DewDepartment of Clinical Biochemistry, King's College Hospital NHS Foundation Trust, London, U.K.
Lisa MeacockDepartment of Radiology, King's College Hospital NHS Foundation Trust, London, U.K.
David A EliasDepartment of Radiology, King's College Hospital NHS Foundation Trust, London, U.K.
Cajetan F MonizDepartment of Clinical Biochemistry, King's College Hospital NHS Foundation Trust, London, U.K.
Michael E EdmondsDiabetic Foot Clinic, King's College Hospital NHS Foundation Trust, London, U.K.ORCID 0000-0002-8931-0069
King's College Hospital NHS Foundation Trust · GBKing's College - North Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveFractures in Charcot neuro-osteoarthropathy (CN) often fail to heal despite prolonged immobilization with below-knee casting. The aim of the study was to assess the efficacy of recombinant human parathyroid hormone (PTH) in reducing time to resolution of CN and healing of fractures. RESEARCH DESIGN AND

methodsPeople with diabetes and acute (active) Charcot foot were randomized (double-blind) to either full-length PTH (1-84) or placebo therapy, both in addition to below-knee casting and calcium and vitamin D3 supplementation. The primary outcome was resolution of CN, defined as a skin foot temperature difference >2°C at two consecutive monthly visits.

resultsMedian time to resolution was 5 months (95% CI 4, 12) in intervention and 6 months (95% CI 2, 9) in control. On univariate mixed Cox and logistic regression, there was no significant difference in time to resolution between the groups (

conclusionsThis double-blind placebo-controlled trial did not reduce time to resolution or enhance fracture healing of CN. There was no added benefit of daily intervention with PTH (1-84) to below-knee casting in achieving earlier resolution of CN.

Indexed as

Diabetes MellitusFractures, BoneCholecalciferolDouble-Blind MethodHumansParathyroid HormoneCholecalciferolParathyroid Hormone

Identifiers

PMID34088701
PMCPMC8323189
OpenAlexW3165300901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.